Personal Care Products

Freda

Freda released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 900.44 M, actual EPS CNY 0.03

Freda to Release FY2026 Q1 Earnings on April 28 After-Market (BJT)

Freda to Release FY2025 Earnings on April 3 After-Market (BJT), Forecast Revenue CNY 4.19 B, EPS CNY 0.265

Freda released FY2025 9 Months earnings on October 27 After-Market (BJT), actual revenue CNY 2.597 B, actual EPS CNY 0.1417

Freda released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 807.27 M, actual EPS CNY 0.0314

Freda FY2025 Q3 Earnings Release on October 28 After-Market BJT

Freda released FY2025 Semi-Annual Earnings on August 21 After-Market (BJT), Actual Revenue CNY 1.79 B, Actual EPS CNY 0.11

Freda released FY2025 Q2 earnings on August 21 After-Market (BJT), actual revenue CNY 913.46 M, actual EPS CNY 0.0603

Freda FY2025 Semi-Annual Earnings Release on August 22, 2025 (BJT)

Furida Responds to Investors on Medical Device Registration and New Product Launch Progress

Furenda Adds Ophthalmology Concept

Kaiyuan Securities Gives Buy Rating to Fujiada

Furenda Products Included in COVID-19 Infection Treatment Directory

Open Securities Gives Buy Rating to Futureda

Company reports R&D expenditure of about 0.42 billion yuan in Q1

Jubali Introduces Progress in Agricultural Applications and Medical Device Sector

ZY Securities Releases Research Report on Forte

Furenda's Q1 2025 Revenue Down 1.63% Year-over-Year

Fureida Completes Recombinant Humanized Collagen Base and Launches Kemi Brand

Freda released FY2025 Q1 earnings on April 24 After-Market BJT, actual revenue CNY 876.08 M, actual EPS CNY 0.05

600223

The episode of "The Top Line" features Dr. Freda Lewis-Hall discussing the fragile trust in the pharmaceutical industry amid rising misinformation. She emphasizes the importance of listening before messaging and explores how AI and omnichannel outreach can impact patient trust. Dr. Lewis-Hall advocates for rebuilding credibility through individual conversations, highlighting the need for industry-healthcare collaborations and the role of social media in restoring patient confidence.

Fiercepharma

Rebuilding pharma’s credibility in the age of misinformation

Freda announced that its operating revenue in the first half of 2025 was 1.79 billion yuan, a year-on-year decrease of 7.05%. Net profit was 108 million yuan, a year-on-year decrease of 15.16%

Zhitong

Freda: Net profit of 108 million yuan in the first half of 2025, a year-on-year decrease of 15.16%

On August 8th, Freda stated on the interactive platform that the company is currently not planning to make ergotamine its main product

Freda: Currently, it has not planned to make ergotamine its main product

301371

603630

603983

300886

The cosmetics sector continues to decline, with Hyea Aromas falling over 6%, and Lafang, Fuerjia, Freda, Marubi, and others following suit

Fuerjia

Lafang

Marubi

Hyea Aromas

The cosmetics sector continues to decline, with Hyea Aromas falling over 6%

002612

002762

000661

300740

000989

The medical beauty concept fluctuated and rose, with SYG increasing by over 17%, JZT and JFLB hitting the limit up, and Freda, CCHT, LANCY, and others leading in gains

LANCY

JFLB

CCHT

The medical beauty concept fluctuates and rises, with SYG increasing by over 17%

603238

The beauty and personal care sector rose, with NBOND hitting the limit up, SYG rising over 10%, and Bawei, Qingsong, Jiaheng Jiahua, Freda, and Fulejia also following suit

NBOND

Green Pine

JAHEN

The beauty and personal care sector rises, NBOND hits the limit up

300955

600249

The beauty and personal care sector surged sharply, with LMZ hitting the limit up, and JAHEN, Lafang, Hyea Aromas, Freda, and SYG all rising significantly

The beauty and personal care sector surged, LMZ hit the daily limit

301108

The daily chemical sector is strengthening. As of the time of publication, Freda has reached the daily limit, with Lafang, JIEYA, Marubi, Shuiyang, and JAHEN among the top gainers

JIEYA

The daily chemical sector strengthens, Freda hits the limit up

According to the Zhitong Finance APP, Freda disclosed its first-quarter report for 2025, showing that the company achieved revenue of 876 million yuan, a year-on-year decrease of 1.63%; net profit attributable to the parent company was 50.71 million yuan, a year-on-year decrease of 14.1%; and net profit excluding non-recurring gains and losses was 46.99 million yuan, a year-on-year decrease of 9.67%. Basic earnings per share were 0.05 yuan

Freda released its first-quarter performance, with a net profit attributable to shareholders of 50.71 million yuan, a year-on-year decrease of 14.1%

Freda(600223.SH)